A Study Looks at Gefapixant Treatment for Chronic Cough
New research found that gefapixant is associated with a significant reduction in cough frequency in people with unexplained chronic cough.
New research found that gefapixant is associated with a significant reduction in cough frequency in people with unexplained chronic cough.
New research found that gefapixant is associated with a significant reduction in cough frequency in people with unexplained chronic cough.
Read MoreGefapixant (MK-7264) is an investigational, orally administered, selective P2X3 receptor antagonist for the potential treatment of refractory or unexplained chronic cough.
Read MoreAn experimental drug called gefapixant blocks a cellular receptor that’s key to the cough reflex, according to research published in The Lancet Respiratory Medicine.
Read More